Division of Gastroenterology and Hepatology, University of Virginia Health System, Charlottesville, Virginia.
Division of Gastroenterology and Hepatology, University of Virginia Health System, Charlottesville, Virginia.
Clin Gastroenterol Hepatol. 2016 Nov;14(11):1521-1532.e3. doi: 10.1016/j.cgh.2016.05.026. Epub 2016 May 27.
Over the past 2 decades, it increasingly has been recognized that endoscopic retrograde cholangiopancreatography (ERCP) is the most predictable provocateur of acute pancreatitis, with an incidence of more than 15% in high-risk patients. For this reason, there has been considerable interest in the effect of periprocedural drug administration as well as different ERCP techniques on both the incidence and severity of post-ERCP pancreatitis. Although many agents and techniques have shown promise in small clinical studies, the majority of these have failed to yield consistent benefit in larger randomized patient groups. This review summarizes the data on medications and ERCP techniques that have been studied for the prevention of post-ERCP pancreatitis.
在过去的 20 年中,人们越来越认识到内镜逆行胰胆管造影(ERCP)是最可预测的急性胰腺炎诱发因素,高危患者的发病率超过 15%。出于这个原因,人们对围手术期药物治疗以及不同的 ERCP 技术对 ERCP 后胰腺炎的发生率和严重程度的影响产生了浓厚的兴趣。尽管许多药物和技术在小型临床研究中显示出了希望,但其中大多数在更大的随机患者组中并未产生一致的益处。这篇综述总结了用于预防 ERCP 后胰腺炎的药物和 ERCP 技术的数据。